Periyar University receives Rs 1.32 crore from CM's research grant scheme
SALEM: Periyar University has secured a total funding of Rs 1.32 crore from the Chief Minister's Research Grant Scheme. "Five research proposals submitted by faculty members and a research scholar have been selected for the funding, each addressing critical areas in science, technology and environmental sustainability," said vice-chancellor R Subramani in a statement.
A Vidyasagar, a professor in the geology department, has obtained Rs 31.92 lakh for a climate-focused study that evaluates the health effects of water pollutants released from south Indian landmasses into the ocean.
P M Ayyasamy, a professor in the department of microbiology, has received Rs 31.82 lakh for creating a bio-extraction process to recover vital minerals.
D Palanivel, an assistant professor in the department of physics, has been granted Rs 28.56 lakh for his research on the use of 2D nanomaterials in photocatalytic processes.
T Elangovan, an assistant professor in the department of energy science and technology, has been awarded Rs 25.94 lakh for his project aimed at improving the long-term efficiency and operational performance of solid-state colour-sensitive solar cells.
M Stanley Dinakar, a research scholar in the physics department, has received Rs 14.11 lakh for creating a next-generation water purification system.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
37 minutes ago
- Indian Express
Delhi govt schools mandate student-made teaching aids under ‘child-friendly pedagogy' push
Middle school classrooms across Delhi are set to become more interactive and hands-on, as government schools are implementing a new initiative focused on multi-sensory learning through student-created teaching tools. Under the 'Joyful Learning' programme of Samagra Shiksha-Delhi, students in classes 6 to 8 will co-develop teaching-learning materials (TLMs) with their teachers in core subjects, including languages, social science, and mathematics. 'The aim is to move away from rote memorisation and passive listening and instead introduce tools that involve touch, sight, sound and interaction to support learning', said an official. Additionally, the initiatives will be evaluated periodically based on their effectiveness, cost-effectiveness, ease of implementation, and the ability to engage multiple senses. According to a circular issued by the department on July 24, the initiative is designed 'to enable children to become motivated and engaged in classes through observation, experimentation, drawing inferences, model building, rational reasoning, and testability'. It also seeks 'to promote student-teacher collaboration and communication'. All government, New Delhi Municipal Council (NDMC), and Delhi Cantonment Board schools have been instructed to compulsorily adopt this during the 2025–26 academic year. The circular notes, 'Teaching-learning materials are indispensable in modern education because they enrich the learning experience by making it more interactive, accessible, and effective for students, while also providing teachers with better tools to explain, assess, and manage the classroom.' These materials are to be developed using easily available and recyclable resources. 'Incorporating students in the creation encourages deeper engagement, creativity, collaboration, and ownership of learning,' it states. 'If the tools are co-created by teachers and students both, the onus of learning will be on both.' The department explains that in social science, materials such as charts, maps or models help simplify complex ideas. In languages, visual and tactile aids support grammar and vocabulary acquisition. 'Multi-sensory learning with interactive activities caters to varying styles, ensuring that all students can engage with the content effectively,' the circular says. The programme will roll out in four phases. At the school level, exhibitions held between July 15 and August 14 are being taken into consideration. Each school has an Rs 6,000 fund allocated to prepare materials and organise the event. Selected entries will move to the zonal exhibitions from August 20 to 23, followed by district-level rounds in September. A final state-level exhibition will be held in November this year as per the circular. 'This activity evolves the scope of promoting inquiry-based education and will motivate students to think critically and develop an early habit of innovative learning,' the circular states. 'The creation of TLM by students can be an integral part of child-friendly pedagogies because it promotes active engagement, creativity, inclusivity, and collaboration,' it adds.
Mint
an hour ago
- Mint
Let the countdown begin: NISAR is a splendid example of space collaboration
Earlier this month, Wing Commander Shubhanshu Shukla returned to earth after spending 18 days in space. He is only the second Indian to have been to space, and piloted the Space X Dragon with its Axiom-4 crew to the International Space Station (ISS) and back. While this mission was commercially arranged, the activities and experiments that Shukla conducted will aid India in its Gaganyaan human spaceflight programme in the coming years. Also Read: How ISRO's partnership with NASA will boost India's space industry Gaganyaan 1 and 2 are expected to place unmanned crafts in low-earth orbit that will be launched in late 2025 and 2026, respectively. Gaganyaan 3 is expected to launch a crewed craft later in 2026 or early 2027. Shukla himself was trained both at the Yuri Gagarin Cosmonaut Training Centre in Moscow and subsequently at the Johnson Space Center in Houston. Another remarkable area of collaboration between the Indian Space Research Organisation (Isro) and National Aeronautics and Space Administration (Nasa) will come to fruition with the launch at the end of July of a jointly-developed satellite called NISAR. The acronym stands for Nasa-Isro Satellite Aperture Radar. The mission is organized to collect an unprecedented amount of information about our planet's environment. It will scan nearly all of Earth's land and ice surfaces twice every 12 days. This will let us track the expansion and contraction of ice sheets, sea ice and glaciers, plus the deformation of its crust due to natural hazards as well as natural and man-made changes to terrestrial ecosystems. These measurements will be carried out by two radar systems—an L-band system and an S-band system. This dual-band system is the first of its kind in the world. The L-band system was built in the Jet Propulsion Laboratory (JPL) at Nasa and the S-band system at the Space Applications Centre (SAC), Ahmedabad. JPL will additionally provide a high-rate telecom subsystem for scientific data, a solid-state recorder and a payload data subsystem. Isro will provide the satellite bus, a solid-state recorder and a payload data system, in addition to launch services and a launch vehicle. Also Read: Mint Quick Edit | Space tourism: Can Isro beat Blue Origin? The NISAR satellite, which weighs nearly 2400kg, has been moved to Sriharikota in preparation for its launch at the end of this month. It will lift off on Isro's GSLV-F16 rocket and then be placed in a 743km sun-synchronous orbit. There are many exciting space missions around the world this year and the next. These span lunar spaceflight, asteroid and planetary missions, climate and earth science missions and orbital innovation (of which NISAR is an example). Nasa, JAXA, ESA, Isro and CNSA lead almost all these programmes. Today, 55 countries have signed the Artemis Accords—a set of principles guiding peaceful and transparent space exploration, especially of the Moon and Mars. At a time when countries are at loggerheads on earth, civilian space collaboration continues apace. If you look deeper, you will find threads of countries going it alone. The most obvious example is the CNSA, particularly Tiangong, China's space station launched in 2021. While China's stated goal is to make it a collaborative international project, it is currently operated by China alone. Tiangong is technically the third space station, since it follows the Mir Space Station that the Soviet Union (and later Russia) had stationed in low-earth orbit from 1986 to 2001, and the ISS, which was launched nearly 25 years ago and is still operational. Surprisingly, Russia is part of the ISS and has committed to remaining so at least until 2028. China, though, has never been part of the ISS. Also Read: Space race: Is competition among Indian startups ready for lift-off? Geopolitics on Earth is beginning to shape some country collaborations in space. The International Lunar Research Station (ILRS) announced by Roscosmos and CNSA in 2021 is led by Russia and China but includes several other countries like Azerbaijan, Belarus, Pakistan and South Africa. The ILRS has announced plans to power a permanent station on the Moon with a nuclear plant to be operational beginning in 2031. After the Soviet Union's space programme, this is the first space mission that seems like an alternative to Western efforts. Brazil, South Korea and India operate space programmes that are not just independent, but also open to wide global collaboration. India's civilian space effort has distinguished itself with its frugal missions, ability to master complex engineering feats like landing near the Moon's south pole, and its overall success in terms of speed and design effectiveness. Missions that explore the far reaches of our solar system and beyond are better left to countries that have very large space budgets. Also Read: Space mission Axiom 4: The universe can be a family one day Nasa has several telescope-based missions for interstellar space and craft-based missions for Jupiter, Saturn and beyond. India has a fast-growing private space sector, but its best returns on space investment are likely to come from parts of space that are close to earth, like near-earth orbits and the Moon. This priority is reflected in Isro's next few missions, be it the planned launch of large and small payloads, uncrewed and crewed missions to low-earth orbit, or its directional tilt towards an Indian Space Station by 2035. Renewed interest in this sector has brought about a new momentum and opened up exciting possibilities for Indian discoveries in space. P.S: 'We are just an advanced breed of monkeys on a minor planet of a very average star. But we can understand the Universe. That makes us something very special," said cosmologist Stephen Hawking. The author is chairman, InKlude Labs. Read Narayan's Mint columns at
Mint
2 hours ago
- Mint
Indian contract drug makers timed their IPOs right. But is the business worth the premium?
An anticipated shift in the global pharmaceutical supply chain away from China has investors excited about Indian contract research, development and manufacturing organisations (CRDMOs), companies that offer services from early-stage drug discovery to late-stage drug development. Export-focused CRDMOs including Anthem Biosciences, Sai Life Sciences and Divi's Laboratories are trading at expensive valuations, reflecting investor enthusiasm as innovator drug companies look at diversifying and derisking their operations. However, experts cautioned that while CRDMOs are expected to post high growth, their financial performances have yet to reflect it. Bengaluru-based Anthem Biosciences made a stellar debut on the stock exchanges on 21 July, listing on the National Stock Exchange at a premium of 27 percent over its initial public offering price of ₹ 570. The IPO, with an issue size of ₹ 3,395.79 crore, was subscribed 67.42 times. Anthem's stock traded at a price-to-earnings (PE) ratio of 93.24 on 25 July. 'The good news is that… China is a behemoth. So, we have that much headroom to grow,' Ajay Bhardwaj, managing director and chief executive officer, told Mint earlier. About 65% of India's imported bulk drugs and advanced drug intermediates worth $3.5 billion in FY25 came from China, according to the commerce ministry. The government wants to strengthen local manufacturing through an upgraded drugs production-linked incentive scheme as it pushes for self-sufficiency in bulk drugs that go into manufacturing medicines. The Indian CRDMO industry today is worth $3-3.5 billion, making up only 2-3% of the global CRDMO market, which is worth $145 billion. It grew at a compound annual growth rate of 15% from 2019-2024, according to a recent report by BCG and IPSO. The industry is at a tipping point, with strong fundamentals and massive headroom to grow, fueled by competitive advantage in small molecule capabilities, faster startup time, focus on quality and cost advantages, the report noted. Unlike CRDMOs, CDMOs (contract development and manufacturing organisations) are typically involved in manufacturing already commercialised drugs. Sai Life Sciences, which made its market debut in December 2024, traded at ₹ 837 on 25 July, close to its high of about ₹ 851, valuing the company at roughly 102 times trailing earnings and about 8.2 times book value. Divi's Laboratories and Syngene International also traded at premiums, at a PE ratio of 80.31 and 55.09, respectively. In comparison, generic pharmaceutical giants are valued relatively modestly: Sun Pharmaceutical Industries trades at a PE ratio of 37.37, Dr Reddy's Laboratories at 18.84, and Cipla at 23.53. Sai Life Sciences shares are up over 18% since listing on the NSE. Divi's Laboratories gained 35.56% from 30 July 2024 to 28 July 2025, Piramal Pharma rose 20.36%, while Syngene International's shares were down 12.72%. Syngene International, a unit of biopharmaceutical company Biocon, kicked off this fiscal's earnings season last week. It posted an 11% year-on-year rise in revenue from operations to ₹ 875 crore for Q1, a robust start compared to its FY25 performance (4% revenue growth YoY). The management maintained its expectation of revenue growth in the mid‑teens for FY26. Sai Life Sciences delivered 16% revenue growth to ₹ 1,695 crore in FY25. Divi's reported a 19% year-on-year rise in full-year revenue to ₹ 9,360 crore in FY25, while net profit surged 37% to ₹ 2,191 crore. Divi's is expected to post revenue growth of 18% year-on-year in Q1FY26, according to brokerage BNP Paribas. 'The Indian CDMO sub-sector presents a highly promising opportunity as investors view it as a direct beneficiary of the China+1 thematic,' Sunil Khaitan, managing director leading financing in India at Goldman Sachs, told Mint. 'We expect the capital markets activity in this space to further accelerate over the next 6-12 months.' The China-plus one theme – to diversify supply chains and reduce overdependence on China – is a key driver, but it's not just that. CRDMOs are on an aggressive capacity expansion track as they anticipate winning over more clients in the future and bank on technological niches to cater to biotech companies as demand for new technologies and drugs grows. Anthem has expertise in new chemical entities as well as biologics (drugs made from living organisms or their components) and capabilities to work on RNAi (a gene regulatory mechanism), antibody drug conjugates that target and kill cancer cells, peptides (short chains of amino acids), lipids, and oligonucleotides (synthesised nucleic acids). OneSource Specialty Pharma, a subsidiary of Strides Pharma, which listed in January, expects its focus on niche areas such as biologics, drug substances, injectables, and drug-device combinations to drive growth. Its offerings in drug-device combinations, particularly for GLP-1s (hormones that regulate blood sugar levels), which are often sold in pen-filled devices, is expected to be a major growth opportunity. 'We are currently executing a 5x expansion of our cartridge-filling capabilities to meet our customer demand and which will significantly boost future revenue,' CEO Neeraj Sharma told Mint in an emailed response. Anthem Biosciences and Sai Life Sciences did not respond to Mint's queries. Investors are looking at CRDMOs not just for potential growth driven by these tailwinds but also as diversification of their portfolios, experts said. Opportunities in traditional pharma companies with a focus on domestic formulations and US generics are drying up because of a slowdown in new approvals and regulatory issues. 'The investor would like to have exposure to companies and segments which have the potential for high growth and themes of shifting manufacturing from China to India,' Tausif Shaikh, healthcare and pharma analyst at BNP Paribas, told Mint. While CRDMOs have reported steady, mid-teen revenue growth, their performance has not been encouraging enough even as valuations remain expensive, Shaikh pointed out. Unlike sectors such as healthcare services, where one can gauge a company's performance based on metrics like hospital bed occupancy and average revenue per bed, for contract drug manufacturers, management commentary is the main indicator of the company's expected growth and performance, said Shaikh. Most companies report an uptick in interest from innovators to hire their services and have embarked on aggressive capacity expansion. Syngene plans to boost its biologics manufacturing footprint in FY26 through its newly acquired US facility for $36.5 million. Divi's Laboratories is undertaking a ₹ 650-700 crore capacity expansion at its existing facilities, while Sai Life Sciences has completed the second phase of its Bidar Unit IV capacity expansion for small-molecule active pharmaceutical ingredients and intermediates. On the back of this, the growth outlook remains strong. "Earnings are expected to be strong for export-oriented CDMOs for the next 2-3 years considering the capex projects and potential addition of new molecules,' Shrikant Akolkar, pharma equity research analyst at brokerage Nuvama, told Mint. However, the CDMO business is non-linear, Akolkar said, adding that one must pay attention to the annual performance and not a couple of quarters of number misses.
